↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Stratmann F.) "

Search: WFRF:(Stratmann F.)

Result 1-10 of 27

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Jukema, JW, et al. (author) Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1167-1176 Journal article (peer-reviewed)
2.	Ray, KK, et al. (author) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 2019 In: The lancet. Diabetes & endocrinology. - 2213-8595 .- 2213-8587. ; 7:8, s. 618-628 Journal article (peer-reviewed)
3.	Roe, MT, et al. (author) Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes 2019 In: Circulation. - : Ovid Technologies (Wolters Kluwer Health). - 1524-4539 .- 0009-7322. ; 140:19, s. 1578-1589 Journal article (peer-reviewed)
4.	Szarek, M, et al. (author) Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial 2019 In: Circulation. Cardiovascular quality and outcomes. - : Ovid Technologies (Wolters Kluwer Health). - 1941-7705 .- 1941-7713. ; 12:11, s. e005858- Journal article (peer-reviewed)
5.	Szarek, M, et al. (author) Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 73:4, s. 387-396 Journal article (peer-reviewed)
6.	Bittner, VA, et al. (author) Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome 2020 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 75:2, s. 133-144 Journal article (peer-reviewed)
7.	Goodman, SG, et al. (author) Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1177-1186 Journal article (peer-reviewed)
8.	Schwartz, GG, et al. (author) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome 2018 In: The New England journal of medicine. - : MASSACHUSETTS MEDICAL SOC. - 1533-4406 .- 0028-4793. ; 379:22, s. 2097-2107 Journal article (peer-reviewed)
9.	Ridker, PM, et al. (author) Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients 2017 In: The New England journal of medicine. - 1533-4406 .- 0028-4793. ; 376:16, s. 1527-1539 Journal article (peer-reviewed)
10.	Keskinen, H., et al. (author) Evolution of Nanoparticle Composition in CLOUD in Presence of Sulphuric Acid, Ammonia and Organics 2013 In: NUCLEATION AND ATMOSPHERIC AEROSOLS. - : American Institute of Physics (AIP). - 9780735411524 ; , s. 291-294 Conference paper (peer-reviewed)abstract In this study, we investigate the composition of nucleated nanoparticles formed from sulphuric acid, ammonia, amines, and oxidised organics in the CLOUD chamber experiments at CERN. The investigation is carried out via analysis of the particle hygroscopicity (size range of 15-63 nm), ethanol affinity (15-50nm), oxidation state (<50 nm), and ion composition (few nanometers). The organic volume fraction of particles increased with an increase in particle diameter in presence of the sulphuric acid, ammonia and organics. Vice versa, the sulphuric acid volume fraction decreased when the particle diameter increased. The results provide information on the size-dependent composition of nucleated aerosol particles.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-10 of 27

Refine your search

Type of publication: journal article (26); conference paper (1)

Type of content: peer-reviewed (27)

Author/Editor: Li, Y. (9); Schmidt, E. (9); Katz, A. (9); Jukema, JW (9); Kim, C. (9); Malik, A (9); show more...; Fazekas, F. (9); Ferrari, E. (9); Filardi, PP (9); Mach, F (9); Müller, C. (9); Witt, N (9); Shechter, M (9); Probst, V. (9); Laufs, U (9); Baranova, E (9); de Silva, HA (9); Stellbrink, C (9); Dion, D (9); Kim, SH (9); Rasmanis, G (9); Aylward, PE (9); Moriarty, PM (9); Karpov, Y (9); Murin, J (9); Tunon, J (9); Chiang, CE (9); Sritara, P (9); Caccavo, A (9); Mackinnon, IJ (9); Codutti, OR (9); Jure, HO (9); Zaidman, CJ (9); Vico, ML (9); Carnero, GS (9); Colombo, HR (9); Luquez, HA (9); Colquhoun, D (9); Carroll, PA (9); Faes, D (9); Hermans, K (9); De Wolf, L (9); Vervoort, G (9); Roosen, J (9); Cools, F (9); Reis, G (9); Nicolau, JC (9); Silva, RP (9); Maia, LN (9); Rossi, PRF (9); show less...

University: Lund University (10); Karolinska Institutet (10); Uppsala University (9); University of Gothenburg (6); Stockholm University (2); Chalmers University of Technology (1)

Language: English (27)

Research subject (UKÄ/SCB): Natural sciences (17); Medical and Health Sciences (9)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view